If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
SensiGen Proprietary AttoSense(TM) Assays for HPV, Cervical Cancer and Other Diseases Complement Sequenom’s Growing Noninvasive Test Portfolio SAN DIEGO & ANN ARBOR, Mich.–(HSMN NewsFeed)–Jan. 26, 2009–Sequenom, Inc. (NASDAQ:SQNM) announced an agreem…
Diagnostics, Acquisitions
Sequenom, SensiGen, AttoSense
Posts from ‘January, 2009’
Sequenom Expands Molecular Diagnostics Portfolio with Acquisition of SensiGen
CardioNet Board of Directors Appoints Randy Thurman Interim President and Chief Executive Officer
Reconfirms Full Year 2008 Financial Guidance; Schedules Investor Conference call CONSHOHOCKEN, Pa., Jan 26, 2009 –(HSMN NewsFeed)– CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology company with an initial focus on the diagnosis and …
Devices, Cardiology, Monitoring, Personnel
CardioNet, cardiac arrhythmia, atrial fibrillation
Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
Mihalik Brings Track Record for Generating Revenue and Profits in the Diabetes Arena SAN DIEGO, Jan. 26 (HSMN NewsFeed) — Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) announced today that Vincent P. Mihalik has been appointed Senior Vice President, Sal…
Biopharmaceuticals, Personnel
Amylin Pharmaceuticals
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Data from SPIRIT III Trial Demonstrate that Patients Treated with XIENCE V Are Less Likely to Have a Heart Attack or Require a Repeat Intervention Out to Two Years ABBOTT PARK, Ill., Jan. 26 (HSMN NewsFeed) — Data published online today in Circulatio…
Devices, Interventional Cardiology
Abbott, XIENCE, Everolimus, Drug Eluting Stent, Coronary Stent
Varian Medical Systems and BrainLAB to Showcase Novalis Tx(TM) Platform for Non-Invasive Image-Guided Radiosurgery
Powerful Technology for the Non-Invasive Treatment of Cancer on Display at the 45th Annual Society of Thoracic Surgeons (STS) Meeting in San Francisco January 25-27, 2009 PALO ALTO, Calif., Jan. 26 (HSMN NewsFeed) — A new non-invasive surgical device…
Devices, Oncology
Varian Clinical Systems, BrainLAB, Novalis Tx, SBRT, radiosurgery
KV Medical Suspends Product Manufacturing, Shipping
Announces Voluntary Product Recall Board of Directors Appoints Special Committee ST. LOUIS, Jan. 26 (HSMN NewsFeed) — KV Clinical laboratory (NYSE: KVa/KVb) has voluntarily suspended the manufacturing and shipping of all of its products, other than certai…
Biopharmaceuticals, Product Recall
KV Medical
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
NEW YORK, January 23, 2009 - (HSMN NewsFeed) - ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the companies have decided, after discussion with the U.S. Foo…
Biopharmaceuticals, Oncology, FDA
Bristol-Myers Squibb, ImClone Systems, Eli Lilly, ERBITUX, cetuximab, NSCLC
Johnson and Johnson Completes Acquisition of Mentor Corporation
NEW BRUNSWICK, N.J., Jan. 23 (HSMN NewsFeed) — Johnson & Johnson (NYSE: JNJ ) today announced the completion of its previously announced acquisition of Mentor Corporation (NYSE: MNT ), a leading supplier of medical products for the global aesthetic mark…
Devices, Mergers & Acquisitions
Johnson & Johnson, Mentor Corp, ETHICON
CLX Clinical, Inc. Issues CEO Comment on Status of Company With Ownership and Planned Distribution of FDA Cleared ThyroTest(R) Product
MURRIETA, CA–Jan 23, 2009 — CLX Lab, Inc. (OTC BB:CLXNE.OB ), which is focused on the marketing and distribution of unique laboratory diagnostic testing products, today issued a statement from CEO Vera Leonard regarding the company’s current career opportunity af…
Diagnostics, Distribution
CLX Pharma, ThyroTest, thyroid stimulating hormone
Protopic(R) Ointment (tacrolimus monohydrate) Receives Positive Opinion for Twice-Weekly use (Maintenance Treatment) in the Treatment of Atopic Dermatitis by the European Medicines Agency
Innovative Treatment Approach Offers Major Step Forward in the Long-Term Management of this Chronic Disease STAINES, England, January 23 (HSMN NewsFeed) — Astellas Pharma Europe Ltd announced today that the Committee for Medicinal Products for Human …
Biopharmaceuticals, Dermatology, Regulatory
Astellas Pharma, Protopic, tacrolimus, Dermatitis
